Abstract:
Background: SLE is a chronic autoimmune illness in which numerous variables, including epigenetic, genetic, and environmental factors, interact to determine disease risk. The role of the VEGF single nucleotide polymorphism (SNP) in SLE patients was assessed in the current study.Aim of The Work:TO determine whether the vascular endothelial growth factor (VEGF) 1154G/A single nucleotide polymorphism (SNP) is associated with systemic lupus erythematosus (SLE) risk & disease activity. Patients and methods: The study included 50 SLE patients and 50 healthy controls. Full clinical assessment and laboratory investigations were done for the SLE patients. For both patients and controls, the (VEGF) 1154G/A SNP was detected using real-time PCR. Systemic Lupus International Collaborating Clinics Damage Index (SLICC DI) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were assessed for SLE patients. Results: the minor A allele of VEGFA (1154G/A) SNP was significantly higher in SLE patients with lower SLICC when compared to the healthy subjects (p-value 0.033). Conclusion: According to the findings, the A allele of VEGFA (rs1570360) SNP may protect against SLE and be linked to a better clinical outcome.